Arjun Agarwal

Oruka SVP Finance Agarwal sells 9,854 shares for $687,035.14 via scheduled 10b5-1 plan; holds 110,000 and 62,708 option shares remaining

Arjun Agarwal, Senior Vice President Finance at Oruka Therapeutics, executed 4 separate sales totaling 9,854 shares for $687,035.14 on 2026-06-12 and 2026-06-15 via a pre-arranged 10b5-1 trading plan. His non-derivative holdings decreased to 16,899 shares post-transaction (from 26,753 shares pre-transaction), while he retains 172,708 aggregate employee stock option shares. The sales occurred at blended average price of $69.72, compared to the current price of $68.86 (now -24.3% from the 52-week high of $91.00). Oruka reported zero revenue in its latest quarter with net income of -$31,820,000 and continues as an unprofitable company. This scheduled equity liquidation under 10b5-1 represents systematic vesting-and-sales at the company's current depressed valuation relative to its 52-week range, occurring within a company experiencing significant operational losses.

SVP Agarwal sells 10,290 shares of ORKA for $607.8K in 4 scheduled transactions under 10b5-1 plan

Arjun Agarwal, Senior Vice President of Finance, executed 4 separate sales on 2026-05-18 totaling 10,290 shares for $607,806.41 at a blended average price of $59.07. This transaction was executed under a pre-arranged 10b5-1 trading plan, meaning the sales were scheduled and not discretionary. Post-transaction, Agarwal holds 16,406 shares, down from 26,696 shares, representing a 38.5% reduction in his holdings. The stock trades at $58.34, down 35.9% from its 52-week high of $91.00, and the company posted $0.00 revenue in the latest quarter with a net loss of $31.8M, indicating ongoing unprofitability. The scheduled nature of this filing precludes attribution of timing intent to the insider.